Evidence map›Paper›PMID 23911668›Full record

ReviewLife sciences2014

Bath salts and synthetic cathinones: an emerging designer drug phenomenon.

Christopher L German, Annette E Fleckenstein, Glen R Hanson

Abstract readHistorical ArticleReview
In one paragraph

Review in Life sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 3 pooled it
15.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 3 syntheses or guidelines pooled it, 346 citations in OpenAlex.

  1. Pooled it
  2. Synthetic Cathinones and Neurotoxicity Risks: A Systematic Review.International journal of molecular sciences · 2023
    Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Exploring the topic structure and abuse trends of new psychoactive Substance since the 21st century from a bibliometric perspective.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Christopher L GermanDepartment of Pharmacology & Toxicology, University of Utah, Salt Lake City, UT 84112, USA. Electronic address: christopher.german@utah.edu.
Annette E FleckensteinDepartment of Pharmacology & Toxicology, University of Utah, Salt Lake City, UT 84112, USA.
Glen R HansonDepartment of Pharmacology & Toxicology, University of Utah, Salt Lake City, UT 84112, USA.
University of Utah · US

Funding

Vmat AND NEUROTOXICITYP01DA013367 · NIDA · UNIVERSITY OF UTAH · PI CROUCH, DENNIS J. · 2001 to 2012
$10.1M
DRUG ABUSE &REGULATORY ENZYMES OF BIOGENIC AMINESR01DA000869 · NIDA · UNIVERSITY OF UTAH · PI FLECKENSTEIN, ANNETTE · 1985 to 2010
$2.9M
Psychostimulants and Monoamine TransportersR01DA011389 · NIDA · UNIVERSITY OF UTAH · PI FLECKENSTEIN, ANNETTE · 2003 to 2012
$2.5M
Role of Neurotensin Systems in Methamphetamine Self AdministrationR01DA031883 · NIDA · UNIVERSITY OF UTAH · PI HANSON, GLEN R · 2012 to 2016
$1.5M
K02 ApplicationK02DA019447 · NIDA · UNIVERSITY OF UTAH · PI FLECKENSTEIN, ANNETTE · 2005 to 2014
$1.3M
Pharmacology and Toxicology of Methamphetamine Abuse (K05 DA00378)K05DA000378 · NIDA · UNIVERSITY OF UTAH · PI HANSON, GLEN R · 1998 to 2011
$1.2M
METHAMPHETAMINE AND DOPAMINE TRANSPORTERSR29DA011389 · NIDA · UNIVERSITY OF UTAH · PI FLECKENSTEIN, ANNETTE · 1998 to 2002
$329k
NIDA NIH HHS DA00378NIDA NIH HHS DA00869NIDA NIH HHS DA11389NIDA NIH HHS DA13367NIDA NIH HHS DA19447NIDA NIH HHS DA31883NIDA NIH HHS K02 DA019447NIDA NIH HHS K05 DA000378NIDA NIH HHS P01 DA013367NIDA NIH HHS R01 DA000869NIDA NIH HHS R01 DA011389NIDA NIH HHS R01 DA031883NIDA NIH HHS R29 DA011389
6 · The paper itself

Abstract

Synthetic cathinones are an emerging class of designer drugs abused for psychostimulant and hallucinogenic effects similar to cocaine, methylenedioxymethamphetamine (MDMA), or other amphetamines. Abuse of synthetic cathinones, frequently included in products sold as 'bath salts', became prevalent in early 2009, leading to legislative classification throughout Europe in 2010 and schedule I classification within the United States in 2011. Recent pre-clinical and clinical studies indicate that dysregulation of central monoamine systems is a principal mechanism of synthetic cathinone action and presumably underlie the behavioral effects and abuse liability associated with these drugs. This review provides insight into the development of synthetic cathinones as substances of abuse, current patterns of their abuse, known mechanisms of their action and toxicology, and the benefits and drawbacks of their classification.

Indexed as

AlkaloidsAnimalsCentral Nervous System StimulantsDesigner DrugsEuropeHallucinogensHistory, 17th CenturyHumansIllicit DrugsLegislation, DrugPsychotropic DrugsSubstance-Related DisordersUnited StatesAlkaloidscathinoneCentral Nervous System StimulantsDesigner DrugsHallucinogensIllicit DrugsPsychotropic DrugsBath saltsDesigner drugsMDPVMephedroneMethyloneStimulantsSynthetic cathinone

Identifiers

PMID23911668
PMCPMC3909723
OpenAlexW2014953635

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.